Efficacy and safely of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression

Clinical Infectious Diseases

Volumn 49, Issue 8, 2009, Pages

  Mira, José A ^a,b,l   Gutiérrez Valencia, Alicia ^c,l   De Gil, Ignacio Los Santos ^e   Merino, Dolores ^f,l   Rivero, Antonio ^g,l   Ríos Villegas, María J ^d,l   Delgado, Marcial ^b,h   González Serrano, Mercedes ^c,l   Collado, Antonio ^i,l   Torres Tortosa, Manuel ^h,j   Omar, Mohamed ^a,l   López Ruz, Miguel Ángel ^k,l   Macias, Juan ^a,b,l   Arponen, Sari ^e   Pineda, Juan A ^a,b,l  

^a Unidad de Enfermedades Infecciosas   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^g Hospital Universitario Reina Sofia Cordoba   (Argentina)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁱ HOSPITAL TORRECÁRDENAS   (Spain)

^j Hospital Punta Europa   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^l Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EMTRICITABINE; GROWTH FACTOR; LAMIVUDINE; MILTEFOSINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TENOFOVIR; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEUTROPENIA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS; IMMUNE DEFICIENCY; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON ALFA-2B; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 70349907659     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605677     Document Type: Article

References (18)

1. 1. Graham CS, Baden LR, Yu E, Mrus JM, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569 (Pubitemid 32709592)
2. 2. Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41:779-789 (Pubitemid 40462940)
3. Berenguer J, Álvarez-Pellicer J, López-Aldeguer J, et al. Sustained virologic response to interferon plus ribavirin reduces liver-related complications and mortality in HIV/HCV-co-infected patients [abstract 60]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). 2008.
4. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from HCV-HIV International Panel. AIDS 2007;21:1073-1089
5. 5. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004; 18:1-12. (Pubitemid 38402312)
6. 6. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS clinical society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88 (Pubitemid 351228130)
7. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for treatment of chronic hepatitis C in patients infected with HIV: Hepatitis-HIV Spanish study group. Clin Infect Dis 1996;23:585-591
8. - cell count. Infection 1998;26:16-19
9. + cells after interferon treatment in HIV-1 infection. Lancet 1993;341:958-959
10. 10. Pesce A, Taillan B, Rosenthal E. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-I infected patients. Lancet 1993; 341:1597. (Pubitemid 23170489)
11. 11. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008;47:36-49. (Pubitemid 351619367)
12. 12. Brau N, Salvatore M., Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55. (Pubitemid 41772515)
13. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002: recommendations of the U.S Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137:435-478
14. 14. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103. (Pubitemid 41772522)
15. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374
16. 16. Valerio L, Yazdanpanah Y, Poizot-Martin I, et al. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2008;47:50-55 (Pubitemid 351619368)
17. 17. Mira JA, Corzo JE, Rivero A, et al. Frequency of visceral leishmaniasis relapses in HIV-infected patients undergoing highly active antiretroviral therapy. Am J Trop Med Hyg 2004;70:298-301. (Pubitemid 38366535)
18. Mira JA, López-Cortés LF, Merino D, et al. Predictors of severe hematological toxicity secondary to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. Antivir Ther 2007;12:1225-1235